Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder

[1]  K. Tansey,et al.  An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. , 2014, The American journal of psychiatry.

[2]  Georgia E. Hodes,et al.  Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress , 2014, Proceedings of the National Academy of Sciences.

[3]  W. Nolen,et al.  Neuroinflammation in bipolar disorder – A [11C]-(R)-PK11195 positron emission tomography study , 2014, Brain, Behavior, and Immunity.

[4]  M. Phillips,et al.  A critical appraisal of neuroimaging studies of bipolar disorder: toward a new conceptualization of underlying neural circuitry and a road map for future research. , 2014, The American journal of psychiatry.

[5]  D. Chuang,et al.  A new avenue for lithium: intervention in traumatic brain injury. , 2014, ACS chemical neuroscience.

[6]  A. Azab,et al.  Effects of lithium on inflammation. , 2014, ACS chemical neuroscience.

[7]  G. Bedi,et al.  Impact of Social Status and Antidepressant Treatment on Neurogenesis in the Baboon Hippocampus , 2014, Neuropsychopharmacology.

[8]  G. Lundkvist,et al.  Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine. , 2013, Journal of psychiatric research.

[9]  H. Hampel,et al.  Increased 3-Hydroxykynurenine serum concentrations differentiate Alzheimer’s disease patients from controls , 2013, European Archives of Psychiatry and Clinical Neuroscience.

[10]  J. Szyndler,et al.  The kynurenine pathway: A missing piece in the puzzle of valproate action? , 2013, Neuroscience.

[11]  F. Giorgini,et al.  Structural basis of kynurenine 3-monooxygenase inhibition , 2013, Nature.

[12]  P. Sklar,et al.  A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder , 2013, Molecular Psychiatry.

[13]  G. Rajkowska,et al.  Hippocampal volume and total cell numbers in major depressive disorder. , 2013, Journal of psychiatric research.

[14]  L. Darlington,et al.  An expanding range of targets for kynurenine metabolites of tryptophan. , 2013, Trends in pharmacological sciences.

[15]  M. Banasr,et al.  Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects. , 2013, The international journal of neuropsychopharmacology.

[16]  M. Landén,et al.  Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder , 2012, Bipolar disorders.

[17]  R. Schwarcz,et al.  Kynurenines in the mammalian brain: when physiology meets pathology , 2012, Nature Reviews Neuroscience.

[18]  T. Stone,et al.  Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection , 2012, The FEBS journal.

[19]  C. Pariante,et al.  Interleukin-1β: A New Regulator of the Kynurenine Pathway Affecting Human Hippocampal Neurogenesis , 2012, Neuropsychopharmacology.

[20]  J. Kocki,et al.  New insight into the antidepressants action: modulation of kynurenine pathway by increasing the kynurenic acid/3-hydroxykynurenine ratio , 2012, Journal of Neural Transmission.

[21]  A. Eisch,et al.  The neurogenesis hypothesis of affective and anxiety disorders: Are we mistaking the scaffolding for the building? , 2012, Neuropharmacology.

[22]  F. McMahon,et al.  Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder , 2012, Journal of psychopharmacology.

[23]  H. Steinbusch,et al.  Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients , 2011, Brain, Behavior, and Immunity.

[24]  B. Bogerts,et al.  Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: Evidence for an immune-modulated glutamatergic neurotransmission? , 2011, Journal of Neuroinflammation.

[25]  R. Schwarcz,et al.  Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration , 2011, Cell.

[26]  R. Dantzer,et al.  Inflammation-associated depression: From serotonin to kynurenine , 2011, Psychoneuroendocrinology.

[27]  E. Jönsson,et al.  Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. , 2010, Journal of psychiatry & neuroscience : JPN.

[28]  J. Price,et al.  Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: The impact of medication , 2010, NeuroImage.

[29]  B. Brew,et al.  Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease , 2009, Journal of Neuroinflammation.

[30]  R. Dantzer,et al.  CSF Concentrations of Brain Tryptophan and Kynurenines during Immune Stimulation with IFN-alpha: Relationship to CNS Immune Responses and Depression , 2009, Molecular Psychiatry.

[31]  W. Drevets,et al.  Bipolar and major depressive disorder: Neuroimaging the developmental-degenerative divide , 2009, Neuroscience & Biobehavioral Reviews.

[32]  Charles L. Raison,et al.  Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression , 2009, Biological Psychiatry.

[33]  H. Steinbusch,et al.  Tryptophan breakdown pathway in bipolar mania. , 2007, Journal of affective disorders.

[34]  R. Coimbra,et al.  Pneumococcal meningitis causes accumulation of neurotoxic kynurenine metabolites in brain regions prone to injury , 2006, Neurobiology of Disease.

[35]  R. Schwarcz,et al.  Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease , 2006, Experimental Neurology.

[36]  J. Kleinman,et al.  Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia , 2005, Neuroscience.

[37]  James C. Overholser,et al.  Cellular changes in the postmortem hippocampus in major depression , 2004, Biological Psychiatry.

[38]  P. L. Le Roux,et al.  Effect of excess extracellular glutamate on dendrite growth from cerebral cortical neurons at 3 days in vitro: Involvement of NMDA receptors , 2003, Journal of neuroscience research.

[39]  G. Giovannoni,et al.  Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients , 2002, Neuroscience Letters.

[40]  A. Chiarugi,et al.  Similarities and differences in the neuronal death processes activated by 3OH‐kynurenine and quinolinic acid , 2001, Journal of neurochemistry.

[41]  Bruce S. McEwen,et al.  Stress and hippocampal plasticity: implications for the pathophysiology of affective disorders , 2001, Human psychopharmacology.

[42]  N. Nishiyama,et al.  Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[43]  A. Salazar,et al.  Quinolinic acid in patients with systemic lupus erythematosus and neuropsychiatric manifestations. , 1996, The Journal of rheumatology.

[44]  M. Beal,et al.  Kynurenine pathway abnormalities in Parkinson's disease , 1992, Neurology.

[45]  C. Grossman,et al.  Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. , 1988, European journal of pharmacology.

[46]  Teresa A. Victor,et al.  Putative Neuroprotective and Neurotoxic Kynurenine Pathway Metabolites Are Associated with Hippocampal and Amygdalar Volumes in Subjects with Major Depressive Disorder , 2015, Neuropsychopharmacology.

[47]  R. Dantzer,et al.  From inflammation to sickness and depression: when the immune system subjugates the brain , 2008, Nature Reviews Neuroscience.

[48]  A. Chiarugi,et al.  Studies on the neuroprotective action of kynurenine mono-oxygenase inhibitors in post-ischemic brain damage. , 2003, Advances in experimental medicine and biology.